Melleva (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol provides estrogenic activity that suppresses the release of follicle‑stimulating hormone, while levonorgestrel supplies progestogenic activity that blocks the luteinizing hormone surge, preventing ovulation. The progestin also thickens cervical mucus and alters the endometrium, creating conditions unfavorable for fertilisation and implantation.

The dosing regimen for Melleva is determined by a qualified prescriber. Typically, the medication is taken as one tablet daily at the same time each day, but the exact schedule and duration should follow the healthcare professional’s instructions.

Melleva is intended for use only when pregnancy is not desired; it is not a treatment for an existing pregnancy. Women who become pregnant should discontinue the product and consult their physician. Breastfeeding mothers should discuss potential risks and benefits with a healthcare provider before using the medication.

To order Melleva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and assists with any necessary import documentation.

Melleva contains the standard dose combination of ethinylestradiol and levonorgestrel, which is comparable to many other combined oral contraceptives on the market. Its efficacy, safety profile and side‑effect spectrum are similar to other EE/LNG products, with differences mainly in tablet formulation, packaging and regulatory approvals.

Melleva tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight and excessive heat to maintain potency throughout its shelf life.

Melleva is taken orally, usually once daily, at the same time each day. The tablet is swallowed whole with water and can be taken with or without food. Consistent daily intake is important to maintain contraceptive effectiveness.

Serious but rare risks include venous thromboembolism, pulmonary embolism, stroke, hepatic adenoma and severe allergic reactions such as anaphylaxis. Women with a history of clotting disorders, smoking over age 35, uncontrolled hypertension or certain liver conditions should discuss these risks with their healthcare provider.

Melleva is contraindicated in women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or are smokers over 35 years of age. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.